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UV Radiation-Induced Immunosuppression Is Greater
in Men and Prevented by Topical Nicotinamide
Diona L. Damian1, Clare R.S. Patterson1, Michael Stapelberg1, Joohong Park1, Ross St.C. Barnetson1 and
Gary M. Halliday1
UV radiation-induced immunosuppression augments cutaneous carcinogenesis. The incidence of skin cancer
continues to increase despite increased use of sunscreens, which are less effective at preventing immuno-
suppression than sunburn. Using the Mantoux reaction as a model of skin immunity, we investigated the effects of
solar-simulated (ss) UV and its component UVA and UVB wavebands and tested the ability of topical nicotinamide
to protect from UV-induced immunosuppression. Healthy, Mantoux-positive volunteers were UV-irradiated on
their backs, with 5% nicotinamide or vehicle applied to different sites in a randomized, double-blinded manner.
Subsequent Mantoux testing at irradiated and adjacent unirradiated sites enabled measurement of UV-induced
immunosuppression with and without nicotinamide. Suberythemal ssUV caused significant immunosuppression,
although component UVB and UVA doses delivered independently did not. Men were immunosuppressed by
ssUV doses three times lower than those required to immunosuppress women. This may be an important cause of
the higher skin cancer incidence and mortality observed in men. Topical nicotinamide prevented immuno-
suppression, with gene chip microarrays suggesting that the mechanisms of protection may include alterations in
complement, energy metabolism and apoptosis pathways. Nicotinamide is a safe and inexpensive compound that
could be added to sunscreens or after-sun lotions to improve protection from immunosuppression.
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INTRODUCTION
Skin cancer is the most common form of malignancy in
Caucasian populations (Diepgen and Mahler, 2002). Immuno-
suppression enhances the development of skin cancers, as seen
most dramatically in transplant recipients whose skin cancer
risk is severalfold higher than that of the immunocompetent
population (Bordea et al., 2004). UV radiation in sunlight has
profound immunosuppressive effects on the skin (Damian et al.,
2001), which play a central role in cutaneous carcinogenesis
(Noonan et al., 2003; Ullrich, 2005). The exact mechanisms of
UV-induced immunosuppression, and the relative contribution
of UVB (290–320nm) and UVA (320–400nm), are as yet unclear.
Various animal and human models of skin immunity have
been used to demonstrate UV-induced immunosuppression
in vivo. UV irradiation can impair both induction (primary
sensitization) and elicitation of immune responses to cuta-
neous allergens (Damian et al., 2001; Wolf et al., 2003).
Systemic UV-induced immunosuppression can be measured
following sensitization at a site distant from the irradiated field,
whereas local immunosuppression is observed when antigen is
applied at the site of UV exposure. Mantoux testing with
tuberculin purified protein derivative (PPD) is used in clinical
practice to assess tuberculosis immunity and exposure status.
Mantoux-positive subjects, who have been either exposed to
tuberculosis or vaccinated with Bacille Calmette-Guerin,
develop localized induration and erythema 48–72 hours after
intradermal injection of PPD. The diameter of induration can
be measured clinically using the ‘‘pen method’’ whereby a
ballpoint pen is used to mark the outer aspects of the Mantoux
response (Bouros et al., 1991). Erythema at reaction sites,
assessed via reflectance spectrometry, provides a more
sensitive measure of Mantoux intensity, which correlates well
with the diameter of induration (Damian and Halliday, 2002).
Men have both a higher incidence of and mortality from
skin cancer (Foote et al., 2001; Molife et al., 2001) but the
effect of gender on susceptibility to UV-induced immuno-
suppression in humans is unknown. Immunosuppression
occurs with UV doses well below the sunburn threshold,
and sunscreens may be less effective at preventing immuno-
suppression than sunburn (Damian et al., 1999; Poon et al.,
2003); improved protection from the immune effects of UV is
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thus likely to reduce the incidence of malignant and
premalignant skin lesions.
Nicotinamide, the active form of vitamin B3, is used
clinically in the treatment of a variety of inflammatory skin
disorders including bullous pemphigoid, acne, and rosacea
(Niren, 2006). Although the exact mechanism of action in these
settings is unknown, nicotinamide is a known endogenous
inhibitor of the nuclear enzyme poly-ADP-ribose polymerase
(PARP), which regulates the expression of immunomodulatory
proteins such as inducible nitric oxide synthase, intercellular
adhesion molecule 1, major histocompatibility complex class II,
and NF-kB (Virag and Szabo, 2002).
Nicotinamide has also been shown to prevent UV-induced
immunosuppression and carcinogenesis in mice (Gensler,
1997, 1999) but its effects on UV immunosuppression in
humans have not yet been investigated. We have previously
shown that UV exposure attenuates Mantoux reactions in
Bacille Calmette-Guerin-vaccinated volunteers (Damian
et al., 1998; Friedmann et al., 2004), and now report the
effects of gender and nicotinamide on UV-induced suppres-
sion of the Mantoux reaction in humans.
RESULTS
Subjects
Of 75 people who started the protocol, 5 did not complete
due to unrelated reasons. None of the subjects who
completed the study were excluded from the results and
none suffered significant adverse effects from the study.
Table 1 shows the similar characteristics of volunteers who
completed the various studies.
Mantoux-induced erythema increases in proportion to PPD dose
Although all subjects had initial Mantoux tests performed the
week before UV irradiation, only 12 volunteers from various
study groups were initially tested with the PPD dose
combination of 1, 2, and 5 U (Figure S1). The erythema
index (EI) of subsequent Mantoux reactions was significantly
correlated with PPD dose, as shown by a repeated measures
linear regression (r¼ 0.705, n¼ 36, Po0.001).
UV irradiation did not cause systemic immunosuppression
The initial, pre-irradiation Mantoux tests (lateral lower back)
were compared with those of unirradiated nicotinamide-
and vehicle-treated controls adjacent to the irradiated areas
(medial lower back). Subjects were excluded from this analysis
if initial PPD doses were different from those subsequently
used. The mean EI of the initial Mantoux tests did not
significantly differ from subsequent control tests in any of the
groups. Therefore, solar-simulated (ss) UV, UVB, or UVA
exposure did not cause systemic suppression of Mantoux
reactions. Nicotinamide in the absence of UV had no immune
effects in any study, as the EI of unirradiated control sites
treated with nicotinamide did not differ from the EI of
unirradiated initial or vehicle-treated sites. Similarly, there
was no significant difference in the unirradiated control EI of
men and women.
Topical 5% nicotinamide prevents ssUV-induced
immunosuppression but not sunburn
The effect of 5% nicotinamide applied before ssUV exposure
in 20 volunteers (10 men, 10 women) is shown in Figure 1a.
Table 1. Baseline characteristics of volunteers
Nicotinamide and ssUV
Nicotinamide before and
after combined1
Characteristic Before (n=20) After (n=20)
Females
(n=18) Males (n=18)
UVA only
(n=15; 7 men)
UVB only
(n=15; 8 men)
Microarray
(n=5; 4 men)
Age (years) (range) 35 (22–63) 38 (23–62) 41 (2563) 32 (2356) 30 (20–54) 31 (20–50) 33 (21–50)
MED J/cm2
ssUV (range)
2.15 (1.11–3.01) 2.06 (0.74–3.72) 2.15 (1.113.75) 2.05 (0.74–3.7) 2.64 (0.79–7.95) not
determined
4.22 (2.69–7.68)
Skin color
Melanin index in
relative units
(range)
76 (129 to
5)
59 (117 to
20)
79 (123 to
36)
60 (129 to
5)
35 (130 to
148)
40 (130 to
25)
58 (105 to
14)
Skin type
I/II/III/IV2 5:9:6:0 5:10:5:0 4:11:3:0 6:6:6:0 6:4:4:1 3:5:7:0 2:2:0:1
Current smokers
Number of
subjects
2 2 2 2 3 2 2
Previous NMSC3 0 2 1 1 1 0 0
MED, minimal erythema dose; NMSC, non-melanoma skin cancer; ssUV, solar-simulated UV.
1Two women and two men participated in both studies therefore one set of each of their results was excluded from analysis.
2Fitzpatrick’s skin types (Fitzpatrick, 1998): I, constitutive skin color pale, does not tan; II, pale, tans with difficulty; III, pale, tans readily; IV, light brown, tans
profusely.
3No patients had previous melanoma.
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Exposure of vehicle-treated skin to 1.48 or 2.22 J/cm2 ssUV
for 3 consecutive days significantly suppressed Mantoux
reactions by 19.4% (mean DEI¼ 13.8, SEM¼ 3.7; Po0.01)
and 27.7% (mean DEI¼19.8, SEM¼2.8; Po0.001), respec-
tively. When irradiated nicotinamide-treated sites were
compared with unirradiated nicotinamide-treated control
sites, significant immunosuppression no longer occurred.
Hence, 5% nicotinamide applied before exposure prevented
ssUV-induced immunosuppression. This protective effect of
nicotinamide treatment was confirmed by repeated measures
analysis of variance (Po0.0001).
The effect of nicotinamide applied immediately after
irradiation in the second group of 20 volunteers (10 men,
10 women) is shown in Figure 1b. There were no significant
differences in baseline characteristics between the two
groups. Three consecutive daily exposures to 0.74 J/cm2
suppressed Mantoux reactions by 24.8% (mean DEI¼16.3,
SEM¼6.2; Po0.05) and exposures to 1.48 and 2.22 J/cm2
caused suppression of 29.1% (mean DEI¼19.2, SEM¼ 6.2;
Po0.05) and 43.8% (mean DEI¼ 28.8, SEM¼5.7;
Po0.001), respectively. At each of the three fixed doses,
significant immunosuppression was prevented by application
of 5% nicotinamide after irradiation. The protective effect of
nicotinamide treatment was again confirmed by repeated
measures analysis of variance (Po0.0001).
The minimal erythema dose (MED) was unchanged by
nicotinamide applied before or after ssUV exposure (Table 2;
paired two-tailed Student’s t-test). Mean erythema (EI) at
vehicle-treated MED sites was not significantly different to the
EI at the nicotinamide-treated site exposed to the same UV
dose whether nicotinamide was applied before or after
ssUV exposure. Hence, nicotinamide did not prevent
sunburn. Spectrophotometry (Ultrospec 2100 pro UV/Visible
Spectrophotometer, Biochrom Ltd, Cambridge, UK) of 5%
nicotinamide in vehicle confirmed negligible absorption
between 290 and 400 nm.
Men are more susceptible to ssUV-induced immunosuppression
than women
To analyze the effects of gender, subjects from both ssUV
studies, in which the irradiation protocols were identical,
were combined. When the studies were analyzed separately,
the results were similar and therefore we present the results of
the combined studies only. Four subjects participated in both
studies. One set of their results was therefore excluded, based
on matching MEDs as evenly as possible for male and female
volunteers. Four of the female volunteers were taking oral
contraceptives, 5 were postmenopausal, and 9 were pre-
menopausal. Because of the small numbers of women in
each group, it was not possible to correlate hormonal status
with susceptibility to immunosuppression.
When ssUV-induced immunosuppression at vehicle-trea-
ted sites was compared between men and women, men were
significantly more immunosuppressed than women (repeated
measures analysis of variance P¼0.0224) and the threshold
dose for immunosuppression was at least three times lower in
men than women (Figure 2). Among male volunteers,
significant immunosuppression was observed at all doses of
ssUV, whereas female volunteers were only significantly
immunosuppressed by the highest dose. Although both men
and women were significantly immunosuppressed by the
highest ssUV dose, immunosuppression was 40% greater in
men. Nicotinamide prevented suppression of Mantoux
responses in both men and women (results not shown). In
this combined group of volunteers, immunosuppression
following exposure to the two highest ssUV doses correlated
to MED (r¼0.587, Po0.001 and r¼0.353, Po0.05,
respectively, using linear regression analysis); subjects who
were more easily sunburned were also more susceptible to
UV immunosuppression.
Component UVB and UVA doses were not independently
immunosuppressive
The effect of irradiation with UVA or UVB alone on the
Mantoux response was investigated in separate groups of 15
volunteers. Subjects were exposed to UVA or UVB on 3
consecutive days at doses equivalent to the UVA and UVB
components of the previously used ssUV doses (0.75, 1.50,
and 2.24 J/cm2 of UVA and 0.075, 0.150, and 0.225 J/cm2 of
UVB). Comparison of Mantoux-induced erythema at irra-
diated and unirradiated sites showed no significant immuno-
suppression at any dose of UVB or UVA. Nicotinamide had
no immune effects in this experiment (Figure S2).
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Figure 1. Topical 5% nicotinamide protects from immunosuppression when
applied before (a) or after (b) ssUV exposure. Results are presented as
meanþ SEM; *Po0.05, **Po0.01, and ***Po0.001 (compared with
unirradiated site, paired two-tailed Student’s t-test; Bonferroni correction
applied; each n¼20).
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Genes involved in complement, energy metabolism and
apoptosis pathways are differentially regulated in
vehicle- and nicotinamide-treated irradiated skin
Six healthy volunteers (five men and one woman) were
recruited for ssUV irradiation, biopsy, and microarray
analysis. In each volunteer, two microarrays were compared
and analyzed (vehicle-treated unirradiated vs vehicle-treated
irradiated sites; and nicotinamide-treated unirradiated vs
nicotinamide-treated irradiated sites). Results from one (male)
volunteer were excluded because of technical inability to
extract the microarray data due to inadequate hybridization.
Gene set enrichment analysis (GSEA) (false discovery rate
p0.25, Po0.05) was applied to identify differentially
regulated functional gene sets. In vehicle-treated skin, no
significantly enriched pathways were upregulated by ssUV
irradiation. Instead, a number of pathways were down-
regulated, including those relating to apoptosis (10 path-
ways), energy metabolism (5 pathways), and immune
function including complement (4 pathways) (Tables S1 and
S2). Highly overlapping genes in apoptosis-related pathways
were protein kinase C (PRKCA), cytochrome c (CYCS),
insulin-like growth factor 1 receptor (IGF1R), BAD, BCL2,
AKT1, caspase 3 (CASP3), HRAS, and TP53. In energy-related
pathways, the leading edge subset of genes in the electron
transport chain pathway (i.e., the genes most responsible for
the enrichment signal) were mitochondrial ATP synthase
(ATP5A1), succinate dehydrogenase complex subunits a and
b (SDHA, SDHB), and cytochrome c (CYCS), which are key
genes in energy production. In the citrate pathway, the
nicotinamide adenine dinucleotide (NADþ )-dependent
enzymes isocitrate dehydrogenase (IDH1, IDH3B) and
succinate-CoA ligase (SUCLG1, SUCLA2) were also down-
regulated. The leading edge subset of genes in complement
pathways were C1Q, C1R, C1S, C4b, and C3. In nicotin-
amide-treated skin, significant downregulation of these path-
ways was no longer observed. Hence, nicotinamide inhibited
ssUV-induced dysregulation of these genes.
In nicotinamide-treated irradiated skin, there was upregu-
lation of the cadmium induces DNA synthesis and prolifera-
tion in macrophages (cdmac) pathway with leading edge
subset genes comprising PLCB1, PRKCA, PRKCB1, HRAS,
CUZD1, MAP2K1 (MEK1 or MKK1), MAPK3 (ERK1), TNF,
and RELA. The histone deacetylase (hdac) pathway (involved
in calcium regulation; McKinsey et al., 2000) was down-
regulated by ssUV in the presence of both vehicle and
nicotinamide (leading edge genes in nicotinamide skin AKT1,
CALM2, CAMK1, HDAC5, MEF2A, MEF2C, and NFATC2).
Pathways for arginine and proline metabolism were also
downregulated in nicotinamide-treated irradiated skin. The
genes in these pathways, involved in energy metabolism such
as providing precursors to the citrate cycle (Davis, 1986)
were NOS3, GOT1, CKM, ASS, SMS, AMD1, CPS1, AOC3,
OAT, and CKMT2.
DISCUSSION
Topical application of nicotinamide prevented UV-induced
immunosuppression when applied either before or after UV
exposure. The ssUV used in this study closely approximated the
spectrum of natural sunlight, and was delivered at doses
equivalent to those readily encountered on a daily basis. ssUV
equivalent to 8 minutes of sun exposure (COLIPA, 1994) on 3
consecutive days caused more than 40% immunosuppression,
and immunosuppression of 25% was caused by UV doses well
below the average MED. Hence, significant immunosuppres-
sion occurred in the absence of sunburn.
Immunosuppression was prevented at all doses tested,
with no adverse effects, when nicotinamide was applied
Table 2. Application of 5% nicotinamide before or after ssUV exposure has no effect on MED
Nicotinamide application Vehicle (Jcm2) Nicotinamide (J/cm2) P-value
Before ssUV MED 2.1570.11 2.1270.12 0.61
EI at MED 8576.82 7975.38 0.214
After ssUV MED 2.0670.19 2.1270.21 0.46
EI at MED 8976.85 8576.68 0.148
EI, erythema index; MED, minimal erythema dose; ssUV, solar-simulated UV.
In 20 volunteers, nicotinamide was applied 15 minutes before MED testing on one side of the back whereas at the same time base lotion was applied on the
other side of the back. There was no significant difference between the mean MED (shown7SEM), nor in the mean EI at skin irradiated with one vehicle-
treated MED (EI at MED) between base lotion-treated sites and nicotinamide-treated sites. In 20 volunteers, nicotinamide was applied immediately after MED
testing on one side of the back and base lotion was applied on the other side of the back. Again, there was no significant difference between the mean MED
between base lotion-treated sites and nicotinamide-treated sites.
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Figure 2. Men are more immunosuppressed by ssUV than women. Results
are presented as mean7SEM; *Po0.01 and **Po0.001 (compared with
unirradiated site, paired two-tailed Student’s t-test; Bonferroni correction
applied; n¼ 36).
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before or after UV exposure. The protective effects of
nicotinamide therefore do not result from sunscreening
activity. This was confirmed by the lack of effect on MED
and negligible UV absorbance by spectrophotometry.
Although the baseline characteristics of the two ssUV groups
were similar, the second group showed higher levels of
immunosuppression. This is likely to reflect normal inter-
individual variation in susceptibility to UV-induced immuno-
suppression (Damian et al., 1998; Kelly et al., 2000).
Individuals who are more susceptible to UV-induced
immunosuppression are at a greater risk of both melanoma
and non-melanoma skin cancer (Yoshikawa et al., 1990);
however, identifying these individuals is difficult as there are
no clinically recognizable signs of cutaneous immunosup-
pression. As previously reported by Kelly et al. (2000), we
found that immunosuppression was significantly correlated to
sunburn threshold; paler-skinned individuals were more
susceptible to not only sunburn, but also UV immuno-
suppression.
We analyzed our microarray data using the innovative,
supervised computational method GSEA (Subramanian et al.,
2005). Compared with unsupervised methods of analysis
such as gene clustering and grouping based solely on gene
expression, the pathway-oriented approach of GSEA is better
able to detect relatively subtle differences between sample
classes and examines entire pathways rather than single
genes. For example, differential activity can be identified
with a mean difference in gene expression of only 20%
(Mootha et al., 2003). Leading edge analysis, showing the
gene sets most responsible for the enrichment signal,
provided additional clues to identify the most critical
subpathways.
Analysis of ssUV-regulated gene expression in vehicle-
treated human skin revealed several downregulated enriched
biological pathways mainly related to complement, apop-
tosis, and energy metabolism. Complement has been shown to
be involved early in the elicitation phase of DTH reactions in
mice (Tsuji et al., 1997), and is also known to be modulated
by UV irradiation (Hammerberg et al., 1998). In humans
exposed to 3 MED of UVB, C3 activation was observed
3–12 hours after irradiation but not at later time points (Terui
et al., 2001). In our study, there was downregulation of
complement pathways in vehicle-treated skin, prevented by
topical nicotinamide. It is possible that ssUV may have
upregulated complement in vehicle-treated skin if biopsies
were performed at an earlier time point, or in response to
higher UV doses.
UV radiation-induced apoptosis is a protective response to
cellular injury that removes potentially genetically damaged
cells from the skin through the formation of sunburn cells
(Melnikova and Ananthaswamy, 2005), although imunohis-
tochemistry of human skin irradiated with very low doses of
ssUV (0.5–1 MED; within the range used in these studies) may
not show any increase in apoptotic cell counts (Murphy et al.,
2002). Our gene array analysis of vehicle-treated skin
showed ssUV-induced downregulation of the IGF-1R signal-
ing pathway including the antiapoptotic genes IGF1R and
AKT1. Also downregulated in vehicle-treated skin was the
programmed cell death pathway, including the antiapoptotic
gene BCL-2. Hence, ssUV exposure had proapoptotic effects
in our transcriptional study. This is consistent with the results
of Enk et al. (2006), who used unsupervised gene clustering
and functional grouping to report microarray findings in
human skin irradiated in vivo with supraerythemal UVB
doses (4 MED) . In contrast with our findings, Enk et al. (2006)
found that UVB differentially regulated several pathways
including those relating to S100 protein, serine protease
inhibitors, and extracellular matrix factors such as metallo-
proteinases as well as apoptosis. This may reflect the much
higher UV dose used. Nicotinamide prevented all of these
effects. The apoptotic genes BCL2, TP53, IGF1R, PRKCA, and
AKT1, comprising the leading edge subset of genes in the Tel
pathway, are involved in regulation of telomerase activity,
which enables the addition of telomeric repeats to telomeres
and is thought to be involved in the early stages of cutaneous
carcinogenesis (Ueda, 2000). UV irradiation increases the
rate of telomere shortening in skin cells (Kosmadaki and
Gilchrest, 2004), consistent with our findings that ssUV
downregulated the telomerase pathway, and suggesting a
protective effect of nicotinamide on this pathway.
Our observed downregulation of genes for energy
production in several pathways in vehicle-treated, irradiated
skin is consistent with ssUV-induced cellular energy deple-
tion (Jacobsen et al., 2001). This pathway was no longer
downregulated in nicotinamide-treated skin, suggesting that
nicotinamide induces changes in energy metabolism as well
as apoptosis. Intracellular nicotinamide is metabolized to
NADþ , the essential coenzyme in ATP production and the
sole substrate of the nuclear enzyme PARP (Hageman and
Stierum, 2001). PARP is involved in multiple cellular
functions, including regulation of p53 expression (Wieler
et al., 2003), and is rapidly activated in response to DNA
damage. Although modest PARP activation enhances DNA
repair, overactivation can cause cell death. Nicotinamide is
an endogenous PARP inhibitor (Hageman and Stierum,
2001); hence PARP inhibition by nicotinamide may have
reduced cellular damage. Like Enk et al. (2006), we found
that ssUV downregulated p53, whereas in the presence of
nicotinamide, p53 downregulation was prevented. Nicotin-
amide has also been shown to alter p53 regulation directly,
independent of PARP (McLure et al., 2004).
The gene expression profile of nicotinamide-treated,
irradiated skin showed upregulation of the enriched pathway
cdmac, which includes genes that overlap with UVA-induced
ERK activation (protein kinase C; PRKCA, PRKCB1, phospho-
lipase C, RAS and the extracellular signal-regulated kinases 1
and 2, ERK, or MAPK3) (He et al., 2004). Direct NADH
insertion is known to increase intracellular calcium (Kaplin
et al., 1996). Phospholipase activation and calcium increase
are required for ERK activation, which plays an important role
in cell proliferation and differentiation. It is possible that a
nicotinamide-induced increase in intracellular calcium might
be an essential upstream signal regulator for the ERK
activation (He et al., 2004).
For the first time, we have shown that ssUV-induced
immunosuppression is greater in men. Only the highest ssUV
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dose caused significant immunosuppression in female
volunteers. In contrast, men were significantly immunosup-
pressed by ssUV doses three times less than the sunburn
threshold, and were more immunosuppressed than women at
all doses tested. Male and female volunteers were well
matched for MED and skin color and were of similar ages.
The incidence of smoking, which not only suppresses
systemic immunity but is also associated with cutaneous
squamous-cell carcinoma (Freiman et al., 2004), was the
same in men and women as was previous history of skin
cancer. Hence, these factors were not a cause of greater
immunosuppression in men.
Similar findings have been reported in mice, where UVB-
induced immunosuppression was significantly greater in
male than in female mice and this was reversed by injecting
males with 17-b-estradiol before irradiation (Hiramoto et al.,
2004). In female mice, ssUV-induced immunosuppression
was exacerbated by topical application of an estrogen
receptor antagonist and attenuated by topical 17-b-estradiol
(Widyarini et al., 2006). Immune cells such as lymphocytes
and macrophages are known to bear sex steroid receptors,
which implies that estrogen may influence cytokine produc-
tion by these cells (Kovacs and Messingham, 2002). Male
gender is an independent risk factor for immunosuppression
following surgical procedures (Wichmann et al., 2003), and
murine studies suggest that testosterone is responsible
(Wichmann et al., 1996). Our findings may explain the
higher female incidence of cutaneous disorders such as
polymorphous light eruption (Mastalier et al., 1998), as well
as the greater skin cancer incidence and mortality observed
in men (Foote et al., 2001; Molife et al., 2001).
In our study, low doses of ssUV (UVAþUVB) were
immunosuppressive but when the UVA and UVB compo-
nents of various ssUV doses were studied individually, we
found that neither UVA alone nor UVB alone was immuno-
suppressive. This suggests that at the very low UV doses used
here, an interaction between the effects of UVA and UVB
leads to immunosuppression, as has been described in studies
of ssUV-induced suppression of contact hypersensitivity to
nickel in nickel-allergic volunteers (Poon et al., 2005).
Immunosuppressive effects may have been detected with
higher individual component doses of UVA and UVB.
In conclusion, we have shown that a likely interactive
effect of UVB and UVA produces ssUV-induced immuno-
suppression at doses well below the sunburn threshold, and
that men are far more susceptible to this immunosuppression
than women. Nicotinamide appeared to mediate its immuno
protective effects by preventing ssUV-induced changes in
complement, apoptosis, and cellular energy pathways,
consistent with its known roles as a PARP inhibitor, ATP
precursor, and anti-inflammatory agent. Nicotinamide also
influenced ssUV-induced transcriptional regulation of genes
in the cdmac and arginine catabolic pathways. Whether this
novel finding is related to the protective effects of nicotin-
amide on the skin requires further investigation with functional
studies. Skin cancer incidence is rising and sunscreens can be
improved by ensuring protection from immunosuppression as
well as sunburn.
MATERIALS AND METHODS
Participants
Healthy Mantoux-positive volunteers who had previously been
vaccinated with BCG were recruited and were required to cease any
vitamin supplementation and avoid sun exposure on their back at
least 4 weeks before and during the study. The study was conducted
according to the Declaration of Helsinki Principles, and approval
was obtained from the Sydney University and Central Sydney Area
Health Service Ethics Committees. All volunteers provided written
informed consent before inclusion.
Study techniques
The UV source, described in detail previously (Damian and
Halliday, 2002), was a 1,000 W xenon arc solar simulator (Oriel,
Stratford, CT), filtered to attenuate visible and infrared wavelengths,
remove UVC (o290 nm), and modify the spectral output so that it
simulated sunlight (ssUV), or comprised predominantly UVB or UVA
only (Damian and Halliday, 2002). Spectra were measured at 1 nm
intervals with an OL754 spectroradiometer (Optronics, Orlando, FL),
which had been calibrated with standard lamps. An IL-1350
broadband radiometer with interchangeable UVA (SED 038) and
UVB (SED 240) detectors (International Light, Newburyport, MA)
was calibrated against the source using the spectroradiometer and
this was used to enable rapid measurement of irradiance before each
irradiation.
One week before irradiation, volunteers were tested with three
different concentrations of tuberculin PPD (CSL Limited, Parkville,
Victoria, Australia), diluted in 0.9% normal saline to a volume of
0.05 ml and injected intradermally on the lower back to confirm
positivity and allow selection of the most appropriate PPD dose for
further testing in each volunteer. Different PPD dose ranges were
used depending on the subjects’ previous reactivity. The intensity of
subsequent Mantoux reactions was assessed 72 hours after injection
using the ‘‘pen method’’ for measuring Mantoux diameter (Bouros
et al., 1991). Only participants with a Mantoux diameter X4 mm
were eligible for the study. Mantoux reactions were also measured
with a reflectance erythema meter (Diastron, Hampshire, UK), which
we have previously found to provide a more sensitive and reliable
measure of changes in skin immunity than diameter (Damian et al.,
1998; Friedmann et al., 2004). Erythema induced by PPD was
calculated as the difference between the EI of the Mantoux response
and the EI of adjacent skin. Erythema meter readings were taken in
triplicate and an average EI for each site was recorded.
Nicotinamide (Fluka Chemie AG, Buchs, Switzerland) was
prepared in 1:2:1 propylene glycol, ethanol, and distilled water
vehicle at a concentration of 5%. The clear, colorless solutions,
prepared fortnightly in our laboratory, were applied (2ml/ cm2)
topically to test sites on the mid- to lower back in a randomized,
double-blinded manner. Subjects were asked to avoid washing the
test sites for at least 8 hours after each application.
Study design
The week after initial Mantoux testing, separate 2.0 2.5 cm areas
on each side of the lower back were irradiated with one of three
fixed doses of ssUV (0.74, 1.48, and 2.22 J/cm2) daily for 3
consecutive days. Adjacent, unirradiated sites on each side served
as immunologically intact controls. Nicotinamide lotion was applied
to test sites on one side of the back, and vehicle to the opposite side,
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15 minutes before or immediately after each ssUV exposure in
separate studies. Mantoux tests were performed at irradiated and
unirradiated sites immediately after the final irradiation and
measured 72 hours later.
Each volunteer’s MED or sunburn susceptibility was determined
by exposing ten 1 cm squares on the upper back to graded ssUV
doses and noting the dose that caused threshold erythema 24 hours
later. The effects of nicotinamide and vehicle on MED were assessed
in all subjects both visually and with the erythema meter. A separate
melanin index function in the erythema meter was used to measure
the skin color of the mid-back.
Additional groups of Mantoux-positive volunteers were recruited
to assess the immune effects of UVB and UVA doses approximating
those contained within the ssUV doses, with nicotinamide applied to
one side of the back and vehicle to the other immediately after
irradiation as described above.
Microarray study
To investigate possible mechanisms of the immune effects of ssUV
and nicotinamide, six volunteers were irradiated with a single, fixed
dose of ssUV (2.22 J/cm2; B0.5 average MED of this group) onto
two areas of their lower backs. These sites were treated with
nicotinamide or vehicle immediately after irradiation, as were two
adjacent, unirradiated sites. Nicotinamide was applied after irradia-
tion to exclude completely any theoretical possibility of a
sunscreening effect of nicotinamide. Twenty-four hours later, a
3 mm punch biopsy was taken from each of the four sites. Total RNA
was extracted using TRIzol reagent (Gibco Invitrogen Life Techno-
logies, Carlsbad, CA), purified and DNase-treated using the RNeasy
Fibrous Tissue Mini Kit (Qiagen Sciences, Valencia, CA), and
amplified using the MessageAmp II aRNA Kit (Ambion Inc., Austin,
TX). Total RNA (60–70mg) was then reverse-transcribed into cDNA
with direct incorporation of cyanine 3-dCTP and cyanine 5-dCTP
fluorescent dyes (Perkin Elmer Life Sciences, Boston, MA). Following
hybridization onto Compugen 19,000 human oligonucleotide
microarray slides (Adelaide Microarray Facility, The University of
Adelaide, Australia), microarrays were scanned using an Axon
scanner (Axon Instruments, Sunnyvale, CA) with GenePix Pro 5.0
software.
Preprocessing and normalization were applied to all microarray
expression data before the assessment of differential gene expres-
sion, using GSEA methodology (Subramanian et al., 2005). To input
microarray data into GSEA, the accession numbers from the
microarrays of normalized treated groups were mapped to corres-
ponding gene symbols using the EASE software in the Database for
Annotation, Visualization, and Integration Discovery (DAVID)
(Dennis et al., 2003; Hosack et al., 2003). GSEA was performed as
previously described using a C2 human-specific gene set library
containing 522 gene sets whose products are involved in specific
metabolic and signaling pathways (Subramanian et al., 2005). We
used the default setting signal-to-noise ranking metric in GSEA to
rank genes. The statistical significance (P-value) of each pathway
was estimated by using phenotype-based permutation estimation
using 1,000 random permutations. We chose pathways with a
significant enrichment score (Po0.05) that had been adjusted for
multiple comparisons using the false discovery rate (qo0.25) for
further interpretation. The false discovery rate is a quantity that
describes for a set of tests that are deemed significant at or below a
given level what proportion of them are likely to be false-positive
findings (Storey and Tibshirani, 2003).
Statistical analysis
Immunosuppression at each site (DEI) was calculated as the
difference between the EI of unirradiated control sites and the EI of
irradiated test sites. Statistical comparisons were made using paired
two-tailed Student’s t-tests, with DEI considered significant if
Po0.05 following Bonferroni correction. All data sets in the
immunosuppression and MED experiments showed normal distri-
bution (Kolmogorov–Smirnov test).
Results are presented as mean7SEM. We analyzed intervention
and immunosuppression using repeated measures analysis of
variance. Correlations were performed using linear regression
analysis or repeated measures linear regression (a random intercept
linear mixed model fitted using STATA v 9.2) as stated.
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SUPPLEMENTARY MATERIAL
Table S1. Summary of GSEA results with FDRo0.25.
Table S2. Genes regulated by ssUV and nicotinamide: rank in gene list.
Figure S1. Mantoux-induced erythema index (EI) increases with the dose of
tuberculin purified protein derivative (PPD).
Figure S2. Low-dose UVB (A) or UVA (B) did not suppress Mantoux-induced
erythema.
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